Shares of Arrowhead Pharmaceuticals rose after the company reported positive interim data from two Phase 1/2 trials for obesity treatments. The stock was up 17%, at $74.61, late Tuesday morning and ...

SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer Models Company's Platform Seeks to Address an Estimated ...

Arrowhead Pharmaceuticals today announced interim results from two Phase I/IIa clinical trials of ARO-INHBE and ARO-ALK7, the ...

Arrowhead Pharmaceuticals reported early trial data showing notable reductions in body, liver, and visceral fat from two experimental obesity drugs, with more results expected in 2026.

Silexion Therapeutics ( ($SLXN) ) has shared an announcement. On January 6, 2026, Silexion Therapeutics released a CEO letter to shareholders ...

SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal ...

Arrowhead Pharmaceuticals, Inc. today announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutics being ...

Arrowhead (ARWR) announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the company’s investigational RNA ...

Arrowhead Pharma (ARWR) stock jumps as obesity drug ARO-INHBE doubles weight loss with Eli Lilly’s (LLY) GLP-1 therapy, ...

Arrowhead Pharmaceuticals recently announced that Health Canada issued a Notice of Compliance for REDEMPLO (plozasiran) as an adjunct treatment to lower triglycerides in adults with familial ...

Detailed price information for Arrowhead Pharma (ARWR-Q) from The Globe and Mail including charting and trades.

A live webcast of the presentation can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events.